BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single Dose

Reuters11-17

Nov 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:

ALNYLAM ANNOUNCES INTERIM PHASE 1 DATA OF NUCRESIRAN (ALN-TTRSC04) SHOWING RAPID KNOCKDOWN OF TTR THAT IS SUSTAINED AT SIX MONTHS FOLLOWING A SINGLE DOSE

Source text: ID:nBw4TkwhWa

Further company coverage: ALNY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484366286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-17 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484366286","market":"us","top_or_hot":-1,"title":"BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single Dose","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single Dose</title></head><body><p><span>Nov 17 (Reuters)</span><span> - </span>Alnylam Pharmaceuticals Inc <span>ALNY.O</span>:</p><ul><li><p>ALNYLAM ANNOUNCES INTERIM PHASE 1 DATA OF NUCRESIRAN (ALN-TTRSC04) SHOWING RAPID KNOCKDOWN OF TTR THAT IS SUSTAINED AT SIX MONTHS FOLLOWING A SINGLE DOSE</p></li></ul><p>Source text: <span>ID:nBw4TkwhWa</span></p><p>Further company coverage: <span>ALNY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single Dose</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single Dose\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-17 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MN0BS:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single DoseNov 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MN0BS:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MN0BS:1","article_id":"2484366286","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484366286","pubTimestamp":1731854431,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single DoseNov 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNY","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4548":"巴美列捷福持仓"},"translate_title":"简介-Alnylam表示Nucresiran(Aln-Ttrsc04)的中期1期数据显示，单次给药后6个月持续快速敲除TTR","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"BRIEF-Alnylam Says Interim Phase 1 Data Of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown Of TTR Sustained At 6 Months Following Single DoseNov 17 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O:ALNYLAM ANNOUNCES INTERIM PHASE 1 DATA OF NUCRESIRAN (ALN-TTRSC04) SHOWING RAPID KNOCKDOWN OF TTR THAT IS SUSTAINED AT SIX MONTHS FOLLOWING A SINGLE DOSESource text: ID:nBw4TkwhWaFurther company coverage: ALNY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484366286"}